Tenofovir Alafenamide(TAF) Reduces the Risk of Hepatocellular Carcinoma(HCC) Recurrence
Clinical trial NCT04290936 · UNKNOWN
Trial details
- NCT number
- NCT04290936
- Sponsor
- Taipei Veterans General Hospital, Taiwan
- Status
- UNKNOWN
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2020-10-16
- Primary completion
- 2023-12-31
- Enrollment
- 402
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.